AIM: CFX
COLEFAX GROUP PLC
("Colefax" or "the Group")
Board Appointment
Colefax Group Plc is pleased to announce the appointment of Timothy ('Tim') Green to the Board as Group Commercial Director with immediate effect. Tim, aged 49, has worked for the Group since September 2018 and became Fabric Division Commercial Director in April 2019.
Tim is the son of Chief Executive David Green and prior to joining Colefax Group was Chief Executive of Tangent Communications Plc, which specialised in digital communication and web design. Tim has brought to the Group a wide range of skills in strategy, planning, management and marketing, and has played an important role in the continued growth and development of the Group over the past six years.
Enquiries:
Colefax Group Plc | David Green, Chief Executive | Tel: 020 7318 6000 |
| Rob Barker, Finance Director | |
KTZ Communications | Katie Tzouliadis Robert Morton | Tel: 020 3178 6378 |
Peel Hunt LLP (Nominated Advisor And Broker) | Dan Webster Andrew Clark | Tel: 020 7418 8900 |
The following information regarding Timothy Benjamin Green is disclosed under Schedule 2(g) of the AIM Rules for Companies:
Current Directorships
| Directorships held in past 5 years |
Colefax and Fowler Limited | Tangent Holdings UK Limited |
The Printed Group Limited | Tangent Labs Limited |
| Tangent Marketing Services Holdco Limited |
| Tangent Marketing Services Limited |
| Tangent Communications Limited |
| Portland Asset Management (UK) Holdco Limited |
| Portland Asset Management (UK) Limited |
Tim Green and Persons Closely Associated ("PCA"s) with him together hold 400,000 shares in Colefax Group Plc. Tim Green holds 250,000 of those shares with the remaining 150,000 shares held by his three children.
There are no other matters which are required to be announced under Schedule 2(g) of the AIM Rules for Companies.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.